nach oben

Current Hepatology Reports

Erschienen in:

10.05.2019 | Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?

verfasst von: Gennaro D’Amico, Giovanni Perricone

Erschienen in: Current Hepatology Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Transition from compensated to decompensated cirrhosis, defined by overt clinical signs, represents a turning point in the clinical course of the disease. In fact, while compensated cirrhosis is a silent disease characterized by long survival, decompensated cirrhosis is associated with symptoms markedly reducing the quality of life and with a median survival of 2–4 years. Therefore, identifying predictors of decompensation and investigating potential interventions for its prevention is a major objective. Mechanisms and incidence of decompensation, together with its predictors, are summarized here, with regard to the etiology of the disease.

Recent Findings

In a total of 92 studies including 105 cohorts and 152,320 patients, the mean ± SD 5-year decompensation rate was 24.5 ± 13.6%. The 5-year decompensation rate was significantly different across different etiologies, ranging from 12.8% for biliary etiologies to 33.6% in alcoholic liver disease (p < 0.0001). The most frequently reported significant predictors of decompensation were liver function, portal hypertension, and inflammation/fibrosis indicators. Etiologic treatment was associated with significant risk reduction.

Summary

While the risk of decompensation significantly varies across different etiologies of cirrhosis, etiology per se has not been properly studied as a decompensation predictor. Although decompensation appears to be related more to inflammation/fibrosis and portal hypertension, the causing factors may determine different activation intensity of the decompensating mechanisms.

Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognosis. Hepatology. 1987;7(1):122–8.CrossRefPubMed

Saunders JB, Walters JRF, Davies P, Paton A. A 20-year prospective study of cirrhosis. Br Med J. 1981;282(6260):263–6.CrossRef

D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.CrossRefPubMed

Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many stages where before there was one: in search of pathophysiological classification of cirrhosis. Hepatology. 2010;51(4):1445–9. https://doi.org/10.1002/hep.23478.CrossRefPubMed

Bedossa P, Garcia-Tsao G, Jain D. Cirrhosis regression and subclassification. Surg Pathol Clin. 2013;6(2):295–309. https://doi.org/10.1016/j.path.2013.03.006.CrossRefPubMed

D’Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V. A morphometric and immunoistochemical study to assess the benefit of sustained virological response in hepatitis c virus patients with cirrhosis. Hepatology. 2012;56(2):532–43. https://doi.org/10.1002/hep.25606.CrossRefPubMed

Vorobioff J, Groszmann R, Picabea E, Gamen M, Villavicenzcio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111(3):701–9.CrossRefPubMed

•• Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S, et al. Effects of an intensive lifestyle intervention program on portal hypertension patients with cirrhosis and obesity: the SportDiet study. Hepatology. 2017;65(4):1293–305. https://doi.org/10.1002/hep.28992 Provides evidence that etiologic cure in obese patients with cirrhosis improves outcome targeting pathophysiologic mechanisms.CrossRefPubMed

•• Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65(4):692–9. https://doi.org/10.1016/j.jhep.2016.05.027 Provides evidence that etiologic cure in HCV cirrhosis improves outcome targeting pathophysiologic mechanisms.CrossRefPubMed

10.

Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(Suppl. 1):S121–31.CrossRefPubMed

11.

Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure up-regulate VEGF and eNOS in the intestinal microcirculation leading to hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006;290:G980–7.CrossRefPubMed

12.

Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut. 2011;60(9):1254–9. https://doi.org/10.1136/gut.2010.235473.CrossRefPubMed

13.

Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol. 2006;44(1):111–7. https://doi.org/10.1016/j.jhep.2005.07.036.CrossRefPubMed

14.

Sethasine S, Jain D, Groszmann R, Garcia-Tsao R. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology. 2012;55(4):1146–53. https://doi.org/10.1002/hep.24805.CrossRefPubMed

15.

Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology. 2009;49(4):1236–44. https://doi.org/10.1002/hep.22745.CrossRefPubMed

16.

•• Villanueva C, Albillos A, Jenescà J, Abraldes J, Calleca JL, Aracil C, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63(1):197–206. https://doi.org/10.1002/hep.28264 First study showing the importance of clinically significant portal hypertension in determining the response to non selective beta-blochers.CrossRefPubMed

17.

De Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33(5):846–52.CrossRefPubMed

18.

Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353(21):2254–61. https://doi.org/10.1056/NEJMoa044456.CrossRefPubMed

19.

Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38(3):266–72.CrossRefPubMed

20.

D’Amico G, Pasta L, Madonia S, Tarantino IG, Mancuso A, Malizia G, et al. The incidence of esophageal varices in cirrhosis. Gastroenterology. 2001;120(Suppl. 1):A2.CrossRef

21.

D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages in cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93. https://doi.org/10.1111/apt.12721.CrossRefPubMed

22.

Gomez Vilar E, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, et al. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol. 2013;58(3):434–44. https://doi.org/10.1016/j.jhep.2012.10.023.CrossRef

23.

Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82. https://doi.org/10.1002/hep.23500.CrossRefPubMed

24.

Zoli M, Merkel C, Magalotti D, Gueli C, Grimaldi M, Gatta A, et al. Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastro. 2000;95(2):503–8. https://doi.org/10.1111/j.1572-0241.2000.01775.x.CrossRef

25.

North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective study. N Engl J Med. 1988;319(15):983–9. https://doi.org/10.1056/NEJM198810133191505.CrossRef

26.

Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146(2):412–19.e3. https://doi.org/10.1053/j.gastro.2013.10.018.CrossRefPubMed

27.

D’Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38(3):599–612. https://doi.org/10.1053/jhep.2003.50385.CrossRefPubMed

28.

Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 1997;25(1):63–70. https://doi.org/10.1053/jhep.1997.v25.pm0008985266.CrossRefPubMed

29.

D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19(4):475–505. https://doi.org/10.1055/s-2007-1007133.CrossRefPubMed

30.

Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Banares R, Albillos A. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149(2):109–22.CrossRefPubMed

31.

Albillos A, Zamora J, Martinez J, Arroyo D, Ahmad I, De-la-Peña J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis. Hepatology. 2017;66(4):1219–31. https://doi.org/10.1002/hep.29267.CrossRefPubMed

32.

Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2379–9. https://doi.org/10.1056/NEJMoa0910102.

33.

Zipprich A, Garcia-Tsao G, Rogowsky S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liv Int. 2012;32(9):1407–14. https://doi.org/10.1111/j.1478-3231.2012.02830.x.CrossRef

34.

Planas R, Montoliu S, Ballesté B, Rivera M, Mireia M, Masnou H, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastro Hepatol. 2006;4(11):1385–94. https://doi.org/10.1016/j.cgh.2006.08.007.CrossRef

35.

•• Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilatation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–84. https://doi.org/10.1016/j.jhep.2015.07.004 This article provides a clear explanation of drawback of the peripheral arterial vasodilatory hypothesis and potential strengths of the bacterial translocation/ inflammation hypothesis in determining decompensation in liver cirrhosis.CrossRefPubMed

36.

Salerno F, Cammà C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34. https://doi.org/10.1053/j.gastro.2007.06.020.CrossRefPubMed

37.

Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–63. https://doi.org/10.1053/j.gastro.2016.09.016.CrossRefPubMed

38.

Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35. https://doi.org/10.1002/hep.27210.CrossRefPubMed

39.

Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS One. 2016;11:e0146076. https://doi.org/10.1371/journal.pone.0146076 eCollection 2016.CrossRefPubMedPubMedCentral

40.

Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33(7):739–47. https://doi.org/10.1111/j.1365-2036.2011.04590.x.CrossRefPubMedPubMedCentral

41.

Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqu MS, et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014;109(11):1757–63. https://doi.org/10.1038/ajg.2014.264.CrossRefPubMedPubMedCentral

42.

Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59(3):482–9. https://doi.org/10.1016/j.jhep.2013.03.039.CrossRefPubMed

43.

Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59(3):474–81. https://doi.org/10.1016/j.jhep.2013.04.036.CrossRefPubMed

44.

Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–74. https://doi.org/10.1016/j.jhep.2014.12.029.CrossRefPubMed

45.

Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62(1):131–7. https://doi.org/10.1136/gutjnl-2011-301255.CrossRefPubMed

46.

Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–8. https://doi.org/10.1016/j.jhep.2011.10.016.CrossRefPubMed

47.

Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi S, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55(6):1241–8. https://doi.org/10.1016/j.jhep.2011.03.012.CrossRefPubMed

48.

Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209. https://doi.org/10.1016/j.jhep.2013.07.044.CrossRefPubMed

49.

Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A, et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gatroenterol. 2017;112(4):588–96. https://doi.org/10.1038/ajg.2017.19.CrossRef

50.

Bajaj JS, O’Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61(8):1219–25. https://doi.org/10.1136/gutjnl-2012-302339.CrossRefPubMed

51.

Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140–8. https://doi.org/10.1053/jhep.2002.30082.CrossRefPubMed

52.

Piano S, Morando F, Carretta G, Tonon N, Vettore E, Rosi S, et al. Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections. Am J Gastroenterol. 2017;112(10):1575–83. https://doi.org/10.1038/ajg.2017.253.CrossRefPubMed

53.

Arvaniti V, D’Amico G, Fede G, Manosou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increases mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–56. https://doi.org/10.1053/j.gastro.2010.06.019.CrossRefPubMed

54.

Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice. J Clin Gastroenterol. 2016;50(2):120–33. https://doi.org/10.1097/MCG.0000000000000446.CrossRefPubMed

55.

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.CrossRefPubMed

56.

Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938–45. https://doi.org/10.1016/j.cgh.2007.02.039.CrossRefPubMed

57.

Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–90. https://doi.org/10.1002/hep.27443.CrossRefPubMed

58.

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38. https://doi.org/10.1055/s-2007-1007122.CrossRefPubMed

59.

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37. https://doi.org/10.1053/j.gastro.2013.02.042.CrossRefPubMed

60.

Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis and clinical characteristics. Semin Liver Dis. 2016;36(2):109–16. https://doi.org/10.1055/s-0036-1583202.CrossRefPubMed

61.

Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–53. https://doi.org/10.1136/gutjnl-2016-312670.CrossRefPubMed

62.

•• Clària J, Stauber ER, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64(4):1249–64. https://doi.org/10.1002/hep.28740 Provides evidence for the inflammatory hypothesis for decompensation of cirrhosis.CrossRefPubMed

63.

Solé C, Solà E, Morales-Ruiz M, Fernandez G, Huelin P, Graupera I, et al. Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis. Sci Rep. 2016;6:32341. https://doi.org/10.1038/srep32341.CrossRefPubMedPubMedCentral

64.

Moreau R. The pathogenesis of ACLF: the inflammatory response and immune function. Semin Liver Dis. 2016;36(2):133–40. https://doi.org/10.1055/s-0036-1583199.CrossRefPubMed

65.

Clària J, Arroyo V, Moreau R. The acute-on-chronic liver failure syndrome, or when the innate immune system goes astray. J Immunol. 2016;197(10):3755–61. https://doi.org/10.4049/jimmunol.1600818.CrossRefPubMed

66.

• Piano S, Tonon M, Vettore E, Stanco M, Pilutti C, Romano A, et al. Incidence, predictors and outcome of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–84. https://doi.org/10.1016/j.jhep.2017.07.008 First study addressing the incidence rate of acute on chronic liver failure in compensated cirrhosis.CrossRefPubMed

67.

Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329–34. https://doi.org/10.1016/j.jhep.2012.10.013.CrossRefPubMed

68.

Ampuero J, Montoliú C, Simón-Talero M, Aguilera V, Millán R, Márquez C, et al. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. J Gastroenterol Hepatol. 2018;33(3):718–25. https://doi.org/10.1111/jgh.13917.CrossRefPubMed

69.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. https://doi.org/10.1053/j.gastro.2015.04.043.CrossRefPubMed

70.

Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther. 2017;46(7):673–80. https://doi.org/10.1111/apt.14243.CrossRefPubMed

71.

Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744–9.CrossRefPubMedPubMedCentral

72.

Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54(2):555–61. https://doi.org/10.1002/hep.24418.CrossRefPubMed

73.

Berzigotti A, Rossi V, Tiani C, Pierpaoli L, Zappoli P, Riili A, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol. 2011;46(5):687–95. https://doi.org/10.1007/s00535-010-0360-z.CrossRefPubMed

74.

Berzigotti A, Zappoli P, Magalotti D, Tiani C, Rossi V, Zoli M. Spleen enlargement on follow-up evaluation: a noninvasive predictor of complications of portal hypertension in cirrhosis. Clin Gastroenterol Hepatol. 2008;6(10):1129–34. https://doi.org/10.1016/j.cgh.2008.05.004.CrossRefPubMed

75.

Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007;13(42):5648–53.CrossRefPubMedPubMedCentral

76.

Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019. https://doi.org/10.1111/apt.15188.

77.

Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104(5):1147–58. https://doi.org/10.1038/ajg.2009.31.CrossRefPubMed

78.

Cacciola I, Filomia R, Alibrandi A, Franzè MS, Caccamo G, Maimone S, et al. Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. Liver Int. 2018;38(7):1220–9. https://doi.org/10.1111/liv.13649.CrossRefPubMed

79.

Calvaruso V, Di Marco V, Bavetta MG, Cabibi D, Conte E, Bronte F, et al. Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2015;41(5):477–86. https://doi.org/10.1111/apt.13051.CrossRefPubMed

80.

Calzadilla-Bertot L, Vilar-Gomez E, Torres-Gonzalez A, Socias-Lopez M, Diago M, Adams LA, et al. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Dig Liver Dis. 2016;48(3):283–90. https://doi.org/10.1016/j.dld.2015.12.002.CrossRefPubMed

81.

Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907. https://doi.org/10.1002/hep.29172.CrossRefPubMed

82.

Chang PE, Wong GW, Li JW, Lui HF, Chow WC, Tan CK. Epidemiology and clinical evolution of liver cirrhosis in Singapore. Ann Acad Med Singap. 2015;44(6):218–25.PubMed

83.

Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267–73. https://doi.org/10.1007/s12072-007-5001-0.CrossRefPubMedPubMedCentral

84.

Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43(2):283–93. https://doi.org/10.1111/apt.13465.CrossRefPubMed

85.

Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol. 2014;60(6):1158–64. https://doi.org/10.1016/j.jhep.2014.02.024.CrossRefPubMed

86.

D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31(5):468–75.CrossRefPubMed

87.

D'Amico G, Pasta L, Morabito A, D'Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93. https://doi.org/10.1111/apt.12721.CrossRefPubMed

88.

Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology. 2016;151(1):130–139.e2. https://doi.org/10.1053/j.gastro.2016.03.036.CrossRefPubMed

89.

Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883–91. https://doi.org/10.1002/hep.20381.CrossRefPubMed

90.

Eaton JE, McCauley BM, Atkinson EJ, Juran BD, Schlicht EM, de Andrade M, et al. Variations in primary sclerosing cholangitis across the age spectrum. J Gastroenterol Hepatol. 2017;32(10):1763–8. https://doi.org/10.1111/jgh.13774.CrossRefPubMedPubMedCentral

91.

Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol. 2007;5(4):502–7. https://doi.org/10.1016/j.cgh.2006.10.016.CrossRefPubMed

92.

Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420–6.CrossRefPubMedPubMedCentral

93.

Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72.CrossRefPubMed

94.

Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82.PubMed

95.

Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97(11):2886–95. https://doi.org/10.1111/j.1572-0241.2002.07057.x.CrossRefPubMed

96.

Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56(4):1439–47. https://doi.org/10.1002/hep.25806.CrossRefPubMed

97.

Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105(10):2164–72; quiz 2173. https://doi.org/10.1038/ajg.2010.294.CrossRefPubMed

98.

Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010;32(11–12):1343–50. https://doi.org/10.1111/j.1365-2036.2010.04473.x.CrossRefPubMed

99.

Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS, et al. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011;54(5):1527–37. https://doi.org/10.1002/hep.24550.CrossRefPubMed

100.

Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, Iacob R, et al. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol. 2005;14(4):329–35.PubMed

101.

Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122–8.CrossRefPubMed

102.

Guha IN, Harris R, Berhane S, Dillon A, Coffey L, James MW, et al. Validation of a model for identification of patients with compensated cirrhosis at high risk of decompensation. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.01.042.

103.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73. https://doi.org/10.1016/j.jhep.2017.07.027.CrossRefPubMed

104.

Hallager S, Ladelund S, Christensen PB, Kjær M, Thorup Roege B, Grønbæk KE, et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol. 2017;9:501–16. https://doi.org/10.2147/CLEP.S132072 eCollection 2017.CrossRefPubMedPubMedCentral

105.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol. 2018;113(2):254–64. https://doi.org/10.1038/ajg.2017.440.CrossRefPubMed

106.

Hernández-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012;107(3):418–27. https://doi.org/10.1038/ajg.2011.456.CrossRefPubMed

107.

Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29(4):1311–6.CrossRefPubMed

108.

Kaplan DE, Serper M, Mehta R, Fox R, John B, Aytaman A, et al. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology. 2019. https://doi.org/10.1053/j.gastro.2019.01.026.

109.

Kim BK, Park YN, Kim DY, Park JY, Chon CY, Han KH, et al. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. Digestion. 2012;85(3):219–27. https://doi.org/10.1159/000335430.CrossRefPubMed

110.

Kim YS, Um SH, Ryu HS, Lee JB, Lee JW, Park DK, et al. The prognosis of liver cirrhosis in recent years in Korea. J Korean Med Sci. 2003;18(6):833–41. https://doi.org/10.3346/jkms.2003.18.6.833.CrossRefPubMedPubMedCentral

111.

King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64(8):1296–302. https://doi.org/10.1136/gutjnl-2014-307862.CrossRefPubMed

112.

Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Okugawa H, et al. Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. Scand J Gastroenterol. 2016;51(2):236–44. https://doi.org/10.3109/00365521.2015.1081275.CrossRefPubMed

113.

Lee MH, Tae HJ, Jun DW, Ryu SE, Choi YY, Kwak MJ, et al. 201Tl heart-liver radioactivity uptake ratio and prediction of decompensation in patients with cirrhosis. Clin Nucl Med. 2013;38(3):169–74. https://doi.org/10.1097/RLU.0b013e31827087e3.CrossRefPubMed

114.

Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13(10):1846–1853.e1. https://doi.org/10.1016/j.cgh.2015.04.013.CrossRefPubMed

115.

Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9(4):235–41.CrossRefPubMed

116.

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31. https://doi.org/10.1056/NEJMoa033364.CrossRefPubMed

117.

Lisotti A, Azzaroli F, Cucchetti A, Buonfiglioli F, Cecinato P, Calvanese C, et al. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. Liver Int. 2016;36(9):1313–21. https://doi.org/10.1111/liv.13070.CrossRefPubMed

118.

Liu TL, Trogdon J, Weinberger M, Fried B, Barritt AS 4th. Diabetes is associated with clinical decompensation events in patients with cirrhosis. Dig Dis Sci. 2016;61(11):3335–45. https://doi.org/10.1007/s10620-016-4261-8.CrossRefPubMed

119.

López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25(7):899–904. https://doi.org/10.1097/QAD.0b013e3283454174.CrossRefPubMed

120.

Macías J, Camacho A, Von Wichmann MA, López-Cortés LF, Ortega E, Tural C, et al. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. AIDS. 2013;27(16):2541–9. https://doi.org/10.1097/QAD.0b013e32836381f3.CrossRefPubMed

121.

Merchante N, Aldámiz-Echevarría T, García-Álvarez M, Rivero-Juárez A, Macías J, Miralles P, et al. Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. J Viral Hepat. 2018;25(2):180–6. https://doi.org/10.1111/jvh.12769.CrossRefPubMed

122.

Merchante N, Rivero-Juárez A, Téllez F, Merino D, José Ríos-Villegas M, Márquez-Solero M, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012;56(1):228–38. https://doi.org/10.1002/hep.25616.CrossRefPubMed

123.

Merchante N, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Merino D, Márquez-Solero M, et al. Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. BMC Infect Dis. 2015;15:557. https://doi.org/10.1186/s12879-015-1291-3.CrossRefPubMedPubMedCentral

124.

Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646–53. https://doi.org/10.1093/cid/cit103.CrossRefPubMed

125.

Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology. 2016;150(2):430–40.e1. https://doi.org/10.1053/j.gastro.2015.10.007.CrossRefPubMed

126.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology. 2018;67(5):1920–30. https://doi.org/10.1002/hep.29717.CrossRefPubMed

127.

Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142–156.e2. https://doi.org/10.1053/j.gastro.2016.09.009.CrossRefPubMed

128.

Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut. 2017;66(2):330–41. https://doi.org/10.1136/gutjnl-2015-310275.CrossRefPubMed

129.

Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis. Scand J Gastroenterol. 2018;53(4):475–81. https://doi.org/10.1080/00365521.2018.1447599.CrossRefPubMed

130.

Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53(5):834–40. https://doi.org/10.1016/j.jhep.2010.06.008.CrossRefPubMed

131.

Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol. 2002;97(8):2063–70. https://doi.org/10.1111/j.1572-0241.2002.05923.x.CrossRefPubMed

132.

Pérez-Latorre L, Sánchez-Conde M, Rincón D, Miralles P, Aldámiz-Echevarría T, Carrero A, et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. Clin Infect Dis. 2014;58(5):713–8. https://doi.org/10.1093/cid/cit768.CrossRefPubMed

133.

Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int. 2016;36(12):1765–73. https://doi.org/10.1111/liv.13156.CrossRefPubMed

134.

Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis. 2009;49(8):1274–82. https://doi.org/10.1086/605676.CrossRefPubMed

135.

Rincón D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol. 2013;48(4):487–95. https://doi.org/10.3109/00365521.2012.711848.CrossRefPubMed

136.

Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8. https://doi.org/10.1053/j.gastro.2007.05.024.CrossRefPubMed

137.

Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–38. https://doi.org/10.1053/j.gastro.2009.01.052.CrossRefPubMed

138.

Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, et al. Clinical outcomes of compensated and decompensated cirrhosis: a long term study. World J Hepatol. 2014;6(7):504–12. https://doi.org/10.4254/wjh.v6.i7.504.CrossRefPubMedPubMedCentral

139.

Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):682–9. https://doi.org/10.1002/hep.21103.CrossRefPubMed

140.

Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One. 2015;10(6):e0128774. https://doi.org/10.1371/journal.pone.0128774 eCollection 2015.CrossRefPubMedPubMedCentral

141.

Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27(5):1435–40. https://doi.org/10.1002/hep.510270535.CrossRefPubMed

142.

Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol. 2013;19(7):1111–8. https://doi.org/10.3748/wjg.v19.i7.1111.CrossRefPubMedPubMedCentral

143.

Smith AD, Zand KA, Florez E, Sirous R, Shlapak D, Souza F, et al. Liver surface nodularity score allows prediction of cirrhosis decompensation and death. Radiology. 2017;283(3):711–22. https://doi.org/10.1148/radiol.2016160799.CrossRefPubMed

144.

Takuma Y, Morimoto Y, Takabatake H, Toshikuni N, Tomokuni J, Sahara A, et al. Measurement of spleen stiffness with acoustic radiation force impulse imaging predicts mortality and hepatic decompensation in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2017;15(11):1782–1790.e4. https://doi.org/10.1016/j.cgh.2016.10.041.CrossRefPubMed

145.

Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol. 2009;24(7):1276–83. https://doi.org/10.1111/j.1440-1746.2009.05851.x.CrossRefPubMed

146.

Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P, et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol. 2014;60(5):948–54. https://doi.org/10.1016/j.jhep.2013.12.023.CrossRefPubMed

147.

Turco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, et al. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol. 2018;68(5):949–58. https://doi.org/10.1016/j.jhep.2017.12.027.CrossRefPubMed

148.

Umemura T, Sekiguchi T, Joshita S, Yamazaki T, Fujimori N, Shibata S, et al. Association between serum soluble CD14 and IL- levels and clinical outcome in primary biliarycholangitis. Liver Int. 2017;37(6):897–905. https://doi.org/10.1111/liv.13316.CrossRefPubMed

149.

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–457.e17. https://doi.org/10.1053/j.gastro.2018.04.034.CrossRefPubMed

150.

Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2018. https://doi.org/10.1002/hep.30368.

151.

Wang JH, Chuah SK, Lu SN, Hung CH, Kuo CM, Tai WC, et al. Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis. Liver Int. 2014;34(9):1340–8. https://doi.org/10.1111/liv.12525.CrossRefPubMed

152.

Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, et al. Influence of progenitor-derived regeneration markers on hepatitis C virus-related cirrhosis outcome (ANRS CO12 CirVir cohort). Hepatology. 2018;68(4):1534–48. https://doi.org/10.1002/hep.29927.CrossRefPubMed

153.

Wong A, Le A, Lee MH, Lin YJ, Nguyen P, Trinh S, et al. Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. Sci Rep. 2018;8(1):7164. https://doi.org/10.1038/s41598-018-25533-2.CrossRefPubMedPubMedCentral

154.

Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J Hepatol. 2018;69(6):1365–70. https://doi.org/10.1016/j.jhep.2018.08.013.CrossRefPubMed

155.

Anika Wranke A, Calle Serrano B, Heidrich B, Kirschner J, Bremer B, Lehmann P, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65:414–25. https://doi.org/10.1002/hep.28876.CrossRefPubMed

Titel: Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?
verfasst von: Gennaro D’Amico
Giovanni Perricone
Publikationsdatum: 10.05.2019
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 2/2019
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-019-00473-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Acute HCV Treatment: What Should We Do in the DAA Era?

HCV Exposure in the Health Care Arena. Is there a Role for Post-exposure Prophylaxis?

HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?

Management of Fatigue in Primary Biliary Cholangitis

HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials

Novel Targets and Drug Development in Portal Hypertension

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin